Featured News
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
AMPEL on Bloomberg Markets
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Local company unveils blood test to find treatments for chronic pain
Local company unveils blood test to find treatments for chronic pain
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
COMPANY
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
PLATFORM
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
PRODUCTS
AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia
Paired with AMPEL’s pipeline of tools to analyze very large and complex clinical datasets (“Big Data”), FibroGENE® is a significant step towards implementing a routine test for monitoring fibromyalgia and providing decision support for treatment based on a patient’s gene expression. This will transform the way doctors treat fibromyalgia by using the information gathered by the lab test and analyzed by bioinformatics to characterize the precise molecular abnormalities and treat symptoms, reduce pain and increase the quality of life of millions of Americans.
AMPEL BioSolutions, Duke Researchers Establish Fibromyalgia Gene Signature
Precision medicine company AMPEL BioSolutions and academic partners at Duke University identified two distinct gene signatures for systemic lupus erythematosus (SLE), one of which appears specific to patients experiencing fibromyalgia.
New Blood Test to Help Physicians Prevent Major Cardiovascular Events in Women with Lupus
Now, a genetic precision medicine test for lupus patients could save lives by predicting heart disease before it happens and providing decision support for prophylactic therapies.
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Researchers have identified shared genetic risk factors for systemic lupus erythematosus and coronary artery disease, according to data published in Cell Reports Medicine.
Heart Disease Blood Test
Ampel Bio-Solutions is working on a blood test that can find out if a person carries traits that may put them at higher risk of developing heart disease.
AMPEL unveils new genetic test for cardiovascular disease in lupus patients
The CardioGENE lab test identifies inherited genetic markers in blood samples which drive pathways to prevent cardiovascular issues with prophylactic targeted treatment
PARTNERS
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.